title: [From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
abstract: The Authors review the natural history of colorectal cancer from the point of view of molecular biology and genetics from aberrant crypts foci and familiar adenomatous polyposis to hereditary non polyposis colon cancer and sporadic colorectal cancer. They carry out international literature about basis knowledges, experimental trials and personal studies. Up to day traditional colorectal cancer surgical treatments and adjuvant or neoadjuvant pharmacological therapy cannot be modified, nevertheless "new drugs generation" known as signal transduction inhibitor could, in the future, prove to be an effective cancer treatment. The Authors highlight recent experimental clinical trials probably able to prevent sporadic colorectal cancer spreading and precursor evolution.
authors.affiliation: II Facoltà di Medicina e Chirurgia, Oncologia, Ospedale Sant'Andrea, Università degli Studi La Sapienza, Roma.
authors.forename: E
authors.initials: E
authors.lastname: Giarnieri
authors.forename: G
authors.initials: G
authors.lastname: Midiri
authors.forename: V A
authors.initials: VA
authors.lastname: Cirolla
authors.forename: A
authors.initials: A
authors.lastname: Covotta
authors.forename: L
authors.initials: L
authors.lastname: Covotta
authors.forename: F M
authors.initials: FM
authors.lastname: Avitto
authors.forename: L
authors.initials: L
authors.lastname: Luzzatto
authors.forename: G
authors.initials: G
authors.lastname: Marino
authors.forename: S
authors.initials: S
authors.lastname: Conte
authors.forename: A
authors.initials: A
authors.lastname: Vecchione
authors.forename: V
authors.initials: V
authors.lastname: Beltrami
mesh_terms: D011125:Adenomatous Polyposis Coli / Q000235:genetics; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000235:genetics; D000068818:Cetuximab; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000601:surgery*; D003123:Colorectal Neoplasms, Hereditary Nonpolyposis / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005500:Follow-Up Studies; D000077156:Gefitinib; D017491:Genes, APC; D016163:Genes, DCC; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D009154:Mutation; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D012106:Research; D013997:Time Factors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D011799:Quinazolines; C116890:Semaxinib; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D000068818:Cetuximab; D000077156:Gefitinib